Assertio Therapeutics
0.70
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About Assertio Therapeutics
Assertio Holdings, Inc. is a leading diversified commercial-stage pharmaceutical company dedicated to providing unique products that offer enhanced therapeutic options for patients in need. On May 19, 2020, Assertio completed a restructuring pursuant to a merger agreement and plan of reorganization. Assertio Therapeutics operates as a wholly owned subsidiary of Assertio Holdings. Company website: http://www.assertiotx.com Company address: 100 South Saunders Road Suite 300 Lake Forest, Illinois 60045
Trade GPT
© 2025 Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.
Rockalpha Limited, operates from its Singapore headquarters at CapitaSky 808, 79 Robinson Road, Singapore 068897, with a regional office at Level 6, Core C, Cyberport 3, 100 Cyberport Road, Hong Kong.